论文信息 - Reply to "Have we reached our final destination with biologics in severe uncontrolled asthma?" - 字舞流文

Reply to "Have we reached our final destination with biologics in severe uncontrolled asthma?"

G. E. Carpagnano | A. Portacci

[1] B. Lipworth,et al. Have we reached our final destination with biologics in severe uncontrolled asthma? , 2023, The journal of allergy and clinical immunology. In practice.

[2] S. Dragonieri,et al. Super-responders to biologic treatment in Type 2 high severe asthma: passing fad or a meaningful phenotype? , 2023, The journal of allergy and clinical immunology. In practice.

[3] Vinh Phu Nguyen,et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. , 2023, The Lancet. Respiratory medicine.

[4] P. Kuna,et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. , 2022, The Lancet. Respiratory medicine.

[5] C. Brightling,et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. , 2021, The Lancet. Respiratory medicine.